XENE
Xenon Pharmaceuticals Inc

2,577
Mkt Cap
$3.15B
Volume
1.06M
52W High
$44.23
52W Low
$26.74
PE Ratio
-10.49
XENE Fundamentals
Price
$40.76
Prev Close
$40.04
Open
$39.86
50D MA
$39.47
Beta
0.79
Avg. Volume
785,924.09
EPS (Annual)
-$3.01
P/B
5.62
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Xenon Pharmaceuticals Inc. $XENE Shares Sold by Candriam S.C.A.
Candriam S.C.A. lowered its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.8% during the second quarter, according to its most recent disclosure with the Securities and...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Nan Fung Trinity HK Ltd. Takes $4.96 Million Position in Xenon Pharmaceuticals Inc. $XENE
Nan Fung Trinity HK Ltd. bought a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the second quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
News Placeholder
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen research firms that are covering the firm, MarketBeat reports. One analyst...
MarketBeat·4d ago
News Placeholder
FY2029 EPS Estimate for Xenon Pharmaceuticals Cut by Analyst
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Wedbush cut their FY2029 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a report issued on Tuesday...
MarketBeat·10d ago
News Placeholder
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Zacks·12d ago
News Placeholder
Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
News Placeholder
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.
Zacks·3mo ago
News Placeholder
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.
Stocktwits·4mo ago
News Placeholder
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Zacks·5mo ago
News Placeholder
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
Zacks·6mo ago

Latest XENE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.